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Abstract
Breast cancer is the leading form of cancer in women, accounting for approximately 41,400 deaths in 2018. While
a variety of risk factors have been identified, physical exercise has been linked to reducing both the risk and
aggressiveness of breast cancer. Within breast cancer, ductal carcinoma in situ (DCIS) is a common finding.
However, less than 25% of DCIS tumors actually progress into invasive breast cancer, resulting in overtreatment.
This overtreatment is due to a lack of predictive precursors to assess aggressiveness and development of DCIS.
We hypothesize that tissue oxygenation and perfusion measured by photoacoustic and contrast-enhanced
ultrasound imaging, respectively, can predict DCIS aggressiveness. To test this, 20 FVB/NJ and 20 SV40Tag mice
that genetically develop DCIS-like breast cancers were divided evenly into exercise and control groups and imaged
over the course of 6 weeks. Tissue oxygenation was a predictive precursor to invasive breast cancer for FVB/NJ
mice (P = 0.015) in the early stages of tumor development. Meanwhile, perfusion results were inconclusive
(P N 0.2) as a marker for disease progression. Moreover, voluntary physical exercise resulted in lower weekly
tumor growth and significantly improved median survival (P = 0.014).
Translational Oncology (2019) 12, 973–980

Introduction
Breast cancer is the most common form of cancer in women. In 2018,
there will be an estimated 266,120 new cases of invasive breast
cancers diagnosed in the United States [1]. This translates to 30% of
all cancers in women. Additionally, 63,960 in situ lesions will be
diagnosed in women [1–4]. Ductal carcinoma in situ (DCIS) is the
most frequent form of in situ breast cancer, referring to a condition
defined as the premalignant proliferation of cells within the breast
ducts and accounting for 83% of newly diagnosed in situ cases [1].
Healthcare costs to treat breast cancer exceed $16.5 billion dollars
per year in the U.S. [2], with an average cost per patient of
approximately $62,000 following diagnosis [5]. The current
paradigm for breast cancer treatments involves a combination of
breast surgery with radiation and chemotherapy of the tumor,
surrounding tissue, or entire breast. Breast cancer is commonly
detected through mammography or manual palpation [1,2,6]. While
mammography can identify tumors at an early stage, this imaging
technique is severely limited in patients with dense breast tissue and
has demonstrated suboptimal specificity [7]. To counteract the
deficiencies of mammography, magnetic resonance imaging (MRI) or
ultrasound are two viable options. MRI is used post-diagnosis as it has
a sensitivity of over 94% [1,7]. However, the high cost and lower

specificity compared to mammography (90% vs. 95%) means MRI is
not currently used as a screening technique [7,8]. Alternatively,
ultrasound is noninvasive, providing real-time imaging modality and
costs a fraction of an MRI. Ultrasound has been shown to detect
cancers that mammography would have missed [9] and shows similar
overall breast anatomy as well as tumor diagnosis as MRI [10].
There is an ongoing clinical need for a predictive precursor for
breast cancer, in particular for the early-stage, high-risk DCIS form.
Only 20 to 25% of all DCIS cases progress into invasive breast cancer,
and studies suggest that an average of 55% of DCIS cases are
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overtreated [2,11]. Recent literature reviews have shown that despite
this rate of overtreatment, there are currently no predictive
biomarkers to determine the aggressiveness and development of
DCIS [1,2,12]. While a variety of environmental and socioeconomic
risk factors have been identified [1–3], studies have shown that
physical exercise reduces the risk of breast cancer mortality by
upwards of 45% by limiting aggressiveness, as well as reducing the
risk of getting diagnosed with breast cancer by 14% [1,10,28]. These
benefits may be attributed to an increase in tissue perfusion and
overall oxygenation state, while also reducing inflammation.
In order to reduce overtreatment of DCIS, parameters to monitor
tumor aggressiveness are needed. Ultrasound is well poised to fill this
role. One emerging trend to characterize tumor growth and
aggressiveness is to quantify tumor hypoxia. Hypoxia has been linked
to advanced tumor progression and angiogenesis [13,14]. This can be
achieved with photoacoustic (PA) imaging. In this modality, light
(typically in the 600–900 nm wavelength range) is directed into the
tissue from a tunable laser and absorbed by tissue chromophores
[15,16]. The optical energy is rapidly absorbed and converted into
heat, resulting in thermoelastic expansion. The rapid expansion
produces a broadband pressure wave that propagates in every
direction, generating acoustic signals that are detected by the
ultrasound transducer. PA imaging enables the measurement of
hemoglobin and blood oxygenation to characterize tumor growth.
Hemoglobin exhibits several absorption bands and this spectrum
changes when binding occurs [16,17]. Oxygenated and deoxygenated
hemoglobin interact differently across the frequency spectrum.
Therefore, by using two wavelengths, most commonly 750 and
850 nm, percent saturation in the blood can be calculated [16]. The
oxygenation saturation of hemoglobin correlates with the metabolic
state of lesions and is thus an important diagnostic parameter [16,17].
Recent studies by our research group have investigated the use of
hemoglobin oxygenation as a breast cancer imaging parameter by
comparing the measurements to angiogenic immunohistochemical
markers [17], while others have studied PA imaging's ability to
differentiate between benign and malignant tumors [19–21].
Moreover, tumor perfusion can be estimated by contrast enhanced
ultrasound (CEUS) [18] for monitoring DCIS progression. This
technique involves intravenously injecting small lipid or polymer
stabilized gas-filled microbubbles typically smaller than 8 μm in
diameter [22,23]. Differences in acoustic impedance between the gas
and surrounding tissue produce up to 25 dB in signal enhancement
[24,25]. This allows for better visualization of angiogenic tumor
vasculature and quantification of perfusion as an indicator of tumor
growth and progression. CEUS has been shown to help differentiate
between benign and malignant tumors [26,27]. Additionally, CEUS
has been used to monitor the effects of physical exercise, a modifiable
risk factor for breast cancer [1,3,28].
Tissue oxygenation and perfusion may become markers to
characterize tumor growth. Therefore, this study investigates these
two parameters as potential biomarkers for DCIS progression using
PA and CEUS imaging in a human breast cancer mouse model.
Materials and Methods

Mouse Model
All animal work was approved by Thomas Jefferson University's
Institutional Animal Care and Use Committee. Twenty FVB/NJ and
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20 Tg(C3–1-TAg)cJeg mice (Jackson Laboratories, Bar Harbor, ME,
USA) were purchased at 9 weeks of age and evenly allocated into
exercise and control subgroups (i.e., 10 mice/group), where the
exercise group had access to a Fisher Scientific (Hampton, NH, USA)
exercise wheel (Figure 1). The Tg(C3–1-TAg)cJeg mice have a SV40
Tag in which they are genetically predisposed to develop breast cancer
in each mammary gland at 10–13 weeks [29]. The tumors appear
similar to DCIS before progressing to invasive breast cancer at
approximately 16 weeks of age. The FVB/NJ mice do not develop
breast cancer.

Animal Preparation
Prior to imaging each week, Nair (Trenton, NJ, USA) was used to
remove hair from the abdomen and leg region. Animals were imaged
over the course of 6 weeks and weighed biweekly until reaching
sacrifice criteria. During imaging days, mice were given anesthesia
using a mixture of oxygen and 3% isoflourane via a nosecone. Mice
were placed on a heating pad at 40 °C during imaging and were
monitored for 30 minutes post-imaging.

Tumor Volume Measurements
Due to their ellipsoidal shape of the tumors, tumor volumes
measurements were obtained weekly on imaging days using a 3D scan
prior to PA and CEUS imaging with a the Vevo 2100 LAZR scanner
(VisualSonics, Toronto, Canada) using a LZ–250 PA probe in
B-mode at 100% power at a transmitting frequency of 21 MHz.
Tumor volumes were monitored only for the SV40 Tag mouse line as
the FVB/NJ mice do not develop any tumors.

Photoacoustic Imaging
PA imaging was performed using a LZ-250 PA probe (VisualSonics). The transducer was aligned along the right hind and leg region
of the mouse, angling from the abdominal mammary gland down
towards the inguinal mammary gland. Once the mouse was correctly
aligned, the laser was fired at 100% power at wavelengths of 750 and
850 nm. PA images were acquired for all mice with a PA gain of 35 dB
and a depth offset of 3 mm for 25 frames. Weekly changes were
calculated with respect to the baseline values at the 9 weeks old time
point for oxygenation measurements.

Contrast-Enhanced Imaging
Immediately following the acquisition of the PA images, CEUS
was performed using a nonlinear contrast mode with the same
LZ-250 probe. Each mouse received a retro-orbital bolus injection of
10 μL of a contrast agent through a 22 gauge blunt needle. The
ultrasound contrast agents SIMB3–4 sized microbubbles (Advanced
Microbubble Laboratories, Boulder, CO) or Vevo MicroMarker®
Target-Ready Contrast Agent (VisualSonics, Toronto, Canada) were
injected. Both contrast agents are specifically designed for high
frequency ultrasound imaging and have identical size (3–4 μm) and
concentrations (2.12 × 10 5 microbubbles/μL). Amplitude modulated flash-replenishment CEUS images were collected at 18 MHz at
4% power (which corresponds to a mechanical index of 0.08) [18]
with a gain of 20 dB and frame rate of 10 Hz. Two destruction bursts
(MI N 0.3) were initiated 20 seconds apart to allow for complete
reperfusion in the mammary gland after the microbubbles were
destroyed from the burst. Changes in weekly values for perfusion
measurements were measured with respect to the 10 weeks old time
point due to poor contrast signal.
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Figure 1. Experimental Design. Mouse model for study consisting of control and experimental subgroups within FVB/NJ and SV40 Tag mouse lines.

Statistical Analysis
All image analysis was performed offline using the Vevo CQ
(VisualSonics, Toronto, Canada) software. For the PA images,
regions of interest (ROIs) were manually outlined around the
mammary gland by a user with 2 years of experience with Vevo CQ
software and verified by a sonographer. (with 6 years of experience)
The values for average tissue oxygenation (SO2) were averaged across
the 25 frames and was used for analysis. For CEUS images, ROIs
were drawn around the skin layer, approximately 1–2 mm deep. Time
intensity curves were created and values for wash-in rate (WIR) was
calculated (as a measure of perfusion) after each destructive burst and
averaged. Lastly, to measure the volumes of the tumors, ROIs were
drawn around the tumor every 2–3 imaging slices and then
extrapolated through the entire tumor to produce a 3D model of
the mammary gland tumor for each mouse. Statistical differences
between exercise and control groups were tested using repeated
measures ANOVA. Lastly, Kaplan–Meier survival curves were
generated to compare the effect of physical exercise. All tests were
performed using a significance value of α ≤ 0.05. Analysis was
performed using SPSS Statistics 25.0.0.0 (IMB, Richmond, VA,
USA).
Results
One FVB/NJ and one SV40 Tag mouse died over the course of the 6
weeks of imaging and were excluded from analysis. Two contrast
agents were needed for this study, due to shelf life issues of the
microbubbles. Significant weight changes were observed between the
exercise and control groups for both the FVB/NJ and SV40 Tag mice.
For the FVB/NJ mice, weekly weight changes were lower for the
exercise group than the control group (3.30 ± 2.46% vs. 7.64 ±
10.36%, P = 0.012). A similar result was obtained for the SV40 Tag
mice between the exercise and control groups (12.09 ± 8.94% vs.
13.62 ± 10.14%, P = 0.039).

Tissue oxygenation and perfusion measurements were analyzed
between the FVB/NJ and SV40 Tag mice, as well as among the
exercise and control subgroups of each mouse line. Example images
for each parameter are shown Figure 2. For tissue oxygenation
measurements, there was no statistical difference found between the
SV40 Tag and FVB mouse lines for either the exercise or control
groups (P = .2; Figure 3). At 10 weeks of age, there was a statistical
difference between the SV40 Tag and FVB/NJ mice in the control
group (P = 0.015). Furthermore, there were no differences in WIR
between exercise groups (P = 0.9) or control (P = 0.2), as shown in
Figure 4. Due to the high variability in the SV40 measurements,
single outliers were removed at the 11 and 14 weeks old time points,
while two outliers were removed for at 12 and 13 weeks. In both the
comparisons of exercise and control subgroups between each mouse
line, there was a greater variation in the SV40 Tag measurements
relative to the FVB/NJ measurements.
Additionally, there was no changes in tissue oxygenation between
the exercise and control groups for the FVB mice (5.16 ± 23.68% vs.
10.93 ± 27.67%, P = 0.5). In comparing the exercise and control
groups of the SV40 Tag mice, average weekly values were higher for
the exercise group than the control group, although this was not
statistically significant (−6.51 ± 26.17% vs. 17.26 ± 25.06%, P =
0.037). Similar to the results when comparing mouse line subgroups,
there were no differences between subgroups in either the FVB/NJ
mice or SV40 Tag mouse line for perfusion measurements
(P N 0.25).
Although there was no statistical difference between the tumor
volumes in the exercise and control groups, the exercise group
exhibited slower tumor growth than compared to the control group at
the early time points (0.38 ± 1.29 mm 3 vs. 0.88 ± 1.28 mm 3, P =
0.21, Figure 5). Furthermore, the exercise mice survived an average of
3 weeks longer than those who had no exercise available (26 weeks vs.
23 weeks, P = 0.014; Figure 6). These differences were associated
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Figure 2. Example PA and CEUS images for FVB/NJ and SV40 Tag Mice. Example images for SV40 Tag of the PA (A) and perfusion (B) are
shown, while example images for the FVB/NJ for PA and perfusion are shown in PanelsC and D, respectively.
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Figure 2. (Continued).
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Figure 3. Comparison of Tissue Oxygenation Measurements. Tissue oxygenation comparison of subgroups between FVB/NJ mouse
lines. The left graph displays differences between exercise groups, while the right shows differences among the control groups.

with both slower primary tumor growth and reduced secondary
tumor formation in the axillary nodes.
Discussion
In the assessment of breast cancer, the transition from DCIS to invasive
carcinoma is controversial. Current treatment options for DCIS can
have serious long-lasting physical, psychological, and financial costs [4].
Understanding the underlying mechanism by which DCIS progresses is
key to minimizing overtreatment. Tissue oxygenation and perfusion are
two markers that have been used to monitor and detect angiogenesis
[18,30], but to date have not been used to predict DCIS formation and
progression. Additionally, studies have found that exercise helps reduce
the risk of breast cancer occurrence, as well as reducing the risk of death
post-diagnosis [1,10,28].
Tissue oxygenation showed the most promising results of the
imaging parameters studied in this project. While there were no
statistical differences between the exercise and control subgroups
when comparing across the SV40 Tag or FVB/NJ mouse lines, due to
a high level of variability (as shown in Figure 5), the control mice
showed higher metastatic tumor growth in axillary nodes as well as
overall tumor growth. Therefore, we can conclude that this as a
precursor biomarker to invasive breast cancer. Moreover, there were
differences in comparing between the exercise and control subgroups

within each mouse line. The statistical difference between the exercise
and control groups of the SV40 Tag mice demonstrated that exercise
group showed a more hypoxic environment, a sign of tumor growth.
Hypoxia has been extensively studied and impacts angiogenesis,
tumor progression, and immune tolerance [31,32].
CEUS has been extensively used to image angiogenesis [18,30],
specifically the effect of physical exercise [33,34], as well as
characterizing tumor growth [30]. Our results (cf., Figure 3) for
tissue perfusion are consistent with findings previously obtained by
Faustino-Rocha et al. [30] that exercise has no effect on perfusion as
there were no differences between the FVB/NJ and SV40 Tag mice
nor their subgroups (P N .2). There was a high degree of variability in
these perfusion measurements, especially within the SV40 Tag mice.
This could be due to several factors, such as limited circulation time
(1–2 minutes), but is most likely due to the type of injections
employed. Orbital eye injections required manual injections and a
study was performed to evaluate the efficiency of manual versus
controlled bolus tail-vein injections [35], which found that controlled
injections improved reproducibility by a factor of 2 to 3 (C = 18.6 ±
8.0% vs. M = 46.7 ± 19.2%, P = 0.02).
While tumor volume measurements were not statistically significant, they did showcase the effects of physical exercise on tumor
growth. The average tumor size was lower in the exercise group than

Figure 4. Comparison of Tissue Perfusion Measurements. Tissue perfusion comparison of subgroups between FVB/NJ mouse lines. The
left graph displays differences between exercise groups, while the right shows differences among the control groups.
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Figure 5. Comparison of Tumor Volume Growth in SV40 Mice Subgroups. Tumor growth comparison of exercise and control SV40
subgroups of mice from 9 to 16 weeks of age.

in the control group (Figure 5). Studies have shown that regular,
moderate to vigorous physical exercise regularly can reduce the risk of
breast cancer by 20 to 40% in postmenopausal women [1,28].
Additionally, this slower tumor growth lead to significantly increased
longevity, as mice who exercised survived an average of 26 weeks,
while the control group lived on average 23 weeks, which was
statistically significant. This was attributed primarily to more frequent
tumor metastases. These results also matched studies that stated
exercise lowers the risk of death post diagnosis by 45% [11].
Our results have demonstrated that tissue oxygenation can be a
predictive precursor for DCIS formation and progression to invasive
carcinoma. These noninvasive tools can be readily translated to the
clinic to potentially guide clinical management of DCIS. Addition-

Figure 6. Survival Curve. Depicts the effect of physical exercise on
survival.

ally, the role of physical exercise is evident on weight changes, slowed
tumor growth, and improvement of median survival.
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